Bladder cancer: innovative approaches beyond the diagnosis

Area of Science:

• Oncology
• Pharmacology
• Urology

Background:

• Bladder carcinoma (BC) is a prevalent urinary malignancy.
• Current therapies for BC are often unsuccessful and accompanied by significant side effects.
• High recurrence rates (up to 90%) and progression to invasive disease necessitate novel therapeutic strategies.

Purpose of the Study:

• To review and highlight innovative pharmacological strategies for bladder carcinoma treatment.
• To investigate recent advancements including epigenetic modulators and endothelin receptor inhibitors.
• To analyze the causes of recurrent bladder carcinoma, focusing on the cellular microenvironment.

Main Methods:

• Literature review of recent and emerging therapeutic approaches for bladder carcinoma.
• Exploration of novel drug candidates, advanced formulations, and natural product-derived compounds.
• Analysis of etiological factors contributing to bladder carcinoma recurrence, with emphasis on the tumor microenvironment.

Main Results:

• Identified several promising new drug candidates, including epigenetic modulators and endothelin receptor inhibitors.
• Highlighted innovative technological formulations and active principles from plants and dietary components.
• Detailed the significant role of the cellular microenvironment in the etiology of recurrent bladder carcinoma.

Conclusions:

• Innovative pharmacological agents and strategies show promise for advancing bladder carcinoma treatment.
• Understanding the tumor microenvironment is crucial for addressing the high incidence of BC recurrence.
• Further research into novel therapies and recurrence factors is warranted to improve patient outcomes.